Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value

$28.26+0.73 (+2.65%)

Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –

Arcutis Biotherapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Arcutis Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Arcutis Biotherapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ARQT.

Revenue growth60.0% · median 8.4%

Gross margin91.2% · median 74.5%

Operating margin6.9% · median -35.4%

Net margin5.9% · median -28.6%

Advertisement
300 × 250

See a number that looks wrong?